FDA confirms minutes for BioCardia's Helix follow-on pre-submission
BioCardia announced the FDA has accepted meeting minutes for the Helix Transendocardial Delivery Catheter, which supports a follow-on De Novo pre-submission to potentially clear the device for market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day